Selection of appropriate chemotherapy drugs and treatment courses depends on factors such as the subtype of breast cancer (e.g., hormone receptor-positive and HER2-positive) and the stage of the disease (early-stage or advanced). Here, ERBB2 is linked to breast cancer.